PubMed Health⌕ Search

Biomedical subjects

L V Elagina

Publications and source records attributed to L V Elagina.

At least 19 recordsLinked to original sources
PubMed2003

[Regional arterial chemoembolisation and chemoimmunoembolisation in combined treatment of colon cancer with hepatic metastases].

Results of locoregional intraarterial treatment with recombinant Interleukine-2 (Ronkoleukine) in patients with hepatic metastases of colon cancer are presented, efficacy of locoregional arterial chemoembolisation and chemoimmunoembolisation in combined treatment of hepatic metastases are evaluated. The drugs were administered through catheter installed in the right or left branch of the own hepatic artery with Selinger method. Endovascular treatment was carried out 6-10 months after removing of primary tumor. In group 1 (8 patients) infusion of 5-fluororuracil during 3 days (2.0 g/day) with subsequent intraarterial immunoembolisation with recombinant Interleukine-2 (Ronkoleukine) 2 mln IU and 10.0 ml lipiodol were performed. In group 2 (13 patients) infusion of 5-fluororuracil during 3 days (2.0 g/day) with subsequent intraarterial chemoembolisation with Doxorubicin 60 mg/kg and 10.0 ml lipiodol were carried out. All the patients underwent cytoreductive surgery on the liver (in the scope from segmentectomy to hemihepatectomy). The patients of group 1 are alive, mean follow-up from removing primary tumor is 22.8 +/- 7.4 months, from start of endovascular treatment--9.2 +/- 2.3 months. Patients of group 2 died due to progression of disease, mean survival from removing primary tumor was 25.7 +/- 4.2 months, from start of endovascular treatment--7.6 +/- 6.3 months. In group 1 postembolic syndrome with transient fever and chill was seen, in group 2--fever, plains in epigastric area, increase of transaminases in blood, abscesses of metastatic tumors (n = 2) and alopecia (in all patients). It is concluded that regional arterial chemoimmunoembolisation is a perspective and safe method in combined treatment of colon cancer with hepatic metastases compared with locoregional chemoembolisation. It increases lifespan and improves quality of life.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed2002

[Perioperative management of focal liver diseases by ofloxacin].

Perioperative use of ofloxacin for prophylaxis was investigated in 20 patients with focal hepatic formations (hemangioma, adenocarcinoma, echinococcosis). First dose of ofloxacin (200 mg) was given intravenously 15 min before operation. After operation ofloxacin was used intravenously (400 mg daily) for 5 days. Pharmacokinetic investigation demonstrated that perioperative intravenous use of ofloxacin provided concentrations in blood and hepatic tissue satisfactory for potential microflore inhibition. Immunological monitoring demonstrated positive dynamics on 5-7 days after operation. dynamics depended on nosology of the focal hepatic formation. Ofloxacin use for prophylaxis in the operated patients with focal hepatic formations was efficient for profilaxy of postoperation infective complications.

Adenocarcinoma↗
PubMed2002

[Current possibilities and perspectives of the combined treatment of patients with severe bronchopulmonary diseases].

Complex treatment with ceftriaxone (or ceftazidime) and intravenous immunoglobulin G (Biaven V. I.) was performed at 21 patients with severe pneumonia and tracheobronchitis complicated by immunedeficient status (myasthenia, diabetes mellitus etc). The results of the treatment proves strong tendency to normalization of the immune system (ceruloplasmin level, CIC, catalase, immunoglobulins) along with clinical signs regression.

Aged↗
PubMed2001

[Experience in the use of vessel due F (sulodexide) in patients with suppurative-necrotic forms of diabetic foot without critical ischemia].

AIM: To evaluate effectiveness of sulodexide in patients with pyonecrotic complications of diabetic foot. MATERIAL AND METHOD: Sulodexide was given to 15 patients which were examined for blood fibrinogen, foot tissues saturation with oxygen, microbic contamination of the wound tissue. In addition, ultrasound dopplerography of foot arteries, laser doppler flowmetry were performed. RESULTS: Fibrinogen in peripheral blood fell, arteriovenous shunting diminished, capillary blood flow and oxygen saturation of the tissues improved. CONCLUSION: Even early sulodexide treatment is effective at different stages of the pathological process in diabetic patients with severe pyonecrotic lesion of the lower limbs as it recovers microcirculatory blood flow.

Diabetic Foot↗
PubMed2001

[Prediction and diagnosis of drug intolerance in patients with purulent infection and burn disease].

The immunological study was made in which the drug sensitivity index according to S. M. Demyanenko was estimated in 76 patients (24 women and 52 men aged 17-73 years): in patients with soft tissue purulent infection (group 1, n = 46) and surface thermal burns (degree III-IV) of 40% body surface (group 2, n = 30). Patients with satisfactory drug tolerance served control (16 patients of group 1 and 10 ones of group 2). Correlations between humoral and cellular immunity parameters and drug sensitivity index were studied. The results may serve a basis for development of early and adequate correction of immunological disorders in the above patients, of drug-related complications caused by immunological imbalance.

Adolescent↗
PubMed1999

[Use of ceftriaxone in the prevention of postoperative purulent complications after surgery on the stomach and small intestine].

Ceftriaxone was administered intravenously in a single dose of 1.0 g 15 minutes prior to surgical intervention for peptic ulcer and gastric or duodenum tumor in 31 patients at the age of 33 to 74 years. In all the patients primary adhesion of the surgical wound was recorded. No signs of local or general infection were observed. The indices of the total blood count, urinalysis and blood biochemical analysis came to normal by the 5th or the 7th day of the postoperative period. The levels of ceftriaxone in the blood, urine, stomach wall, small intestine tissues and subcutaneous fat were evaluated. The indices of the cellular and humoral immunity in the pre- and postoperative periods in the patients prophylactically treated with ceftriaxone were analyzed.

Adult↗
PubMed1999

[Substantiation and varieties of complex surgical treatment tactics for pyo-necrotic forms of diabetic foot].

For the period from 1996 to 1998 in the Division of wounds and wound infection of A.V. Vishnevsky Institute of Surgery 92 patients with pyonecrotic forms of "diabetic foot" underwent thorough examination and treatment. The patients were divided into groups by the form of "diabetic foot": with pyonecrotic forms of "diabetic foot" without critical ischemia (group 1) and with it (group 2). In 18 patients of both groups the data of electron autoradiography were used to reveal peculiarities of the wound process. Group 1 patients had at admittance a large number of neutrophiles in various stages of destruction in biopsies of the wound. In patients of group 2 a great majority of the vessels in biopsies of the wound were in different stages of destruction with lost connections between their separate cells or some of their part absent. Separate cells (endotheliocytes and pericytes) which make up the walls of destroying vessels, were synthesizing RNA and were functionally active. In both groups, the studied parts of the wound before plastic repair of its defect usually represented as well developed granulation tissues with a number of microvessels and cells. Intensive synthesis of PNA in the cells of microvascular wall evidenced of their high functional activity, and the synthesis of DNA in them showed their ability for proliferation, i.g.--for growth. Thus, microangiopathy was reversible, and the solution of the problem of critical ischemia should be considered in the light of macroangiopathy. Thus, in patients of group 1 the cause of pyonecrotic damage consists in infection process, while in patients of group 2--in combination of infection with ischemia of the extremity. In both groups pyonecrotic disease of the extremity ruses at the background of severe disturbances of cellular immunity.

Diabetic Foot↗
PubMed1998

[Diagnostic and prognostic significance of some parameters of nonspecific defense humoral mechanism in patients with lymphedema complicated by erysipelas inflammation].

Immunological investigation of 193 patients with uncomplicated lymphedema and lymphedema complicated with erysepalas inflammation registered in the patients with inflammation high levels of antigen-nonspecific circulating immune complexes, beta-lysins, alpha1-antitripsin, serum IgE and IgM in the presence of massive bacterial infection of the limb skin. The above alterations may serve diagnostic and prognostic indicators of the disease chronicity and progression in patients with lymphedema.

Adolescent↗
PubMed1998

[Clinical and laboratory study of cefodizime (Modivid) in prophylaxis and treatment of surgical patients].

The results of the clinical and laboratory study of the efficacy of the prophylactic and therapeutic use of cefodizime (modivid) in patients with chronic calculous cholecystitis and burns are presented. Expediency of the preoperative prophylactic use of the drug and its significance in the treatment of infectious complications of the burn disease were verified. The immunological investigation gave evidence of an increase of the phagocytosis functional activity when cefodizime (modivid) was used prophylactically in cholecystectomy.

Adolescent↗
PubMed1998

[Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns].

The experience with lomefloxacin and ofloxacin respectively in the complex therapy of 26 and 40 patients with burns is described. The drugs were shown to be highly active in the treatment of burn wound infections and infectious complications of burn disease. The clinical efficacy of lomefloxacin and ofloxacin amounted to 88 and 77.5 per cent and the bacteriological efficacy amounted to 81 and 80 per cent respectively.

Adolescent↗
PubMed1996

[Use of aztreonam for the purpose of preventing postoperative purulent complications].

The efficacy of the prophylactic use of azthreonam, a monocyclic beta lactam antibiotic, was studied in 20 patients operated for liver diseases. The drug was administered intramuscularly in a dose of 1 g 30 minutes prior to the operation. During the postoperative period the drug was administered in a dose of 1 g 4-5 times a day for 4 to 5 days. The clinical effect in all the patients was good: no elevation of the body temperature above 37.5 degrees C and no suppuration of the operation wound. Adverse reaction to the treatment were not observed. 135 clinical isolates were tested for the susceptibility to azthreonam. The most susceptible gram-negative bacteria were the following: E coli (100 per cent), P. mirabilis (100 per cent), M. morganii (100 per cent), P. rettgeri (100 per cent) and Citrobacter sp. (84 per cent). P. aeruginosa, Acinetobacter, P. vulgaris and Enterobacter were less susceptible (64, 50, 50 and 47.5 per cent respectively). All the S. aureus isolates were resistant.

Aztreonam↗
PubMed1996

[Ofloxacin in comprehensive treatment of infections in burn patients].

The experience with ofloxacin in the prophylaxis and treatment of infected burn wounds in 40 patients was investigated. High clinical and microbiological efficacy of the drug was stated (82.5 and 83 per cent respectively). The highest efficacy of ofloxacin was observed when the burned area did not exceed 25 per cent of the body surface. It was concluded that the prophylactic use of the drug during acute burn toxemia was not expedient.

Adult↗
PubMed1995

[Use of imipenem in the treatment of patients with surgical infection].

The efficacy of thienam, a product of Merck, Sharp and Dohme (USA) composed of imipenem and cylastatin was studied in the treatment of 52 patients with surgical infection. In 48 and 4 patients the drug was used therapeutically and prophylactically respectively. When the drug was used therapeutically the recovery and improvement were observed in 41 out of 44 patients (93.2 per cent), 4 patients being excluded from the treatment group because of adverse reactions such as hyperthermia and skin eruption. When the drug was used prophylactically the recovery and improvement were stated in all the 4 patients. The pathogens were eradicated in the wound in 40 patients (91 per cent). 114 clinical isolates were tested and the imipenem resistance was detected only in 6.5 per cent of the Staphylococcus aureus strains, in 20 per cent of the Pseudomonas aeruginosa strains and in 50 per cent of the P. mirabilis and P. vulgaris strains. All the isolates of Escherichia coli, Enterobacter, Acinetobacter and Citrobacter were susceptible or moderately susceptible to imipenem.

Adult↗
PubMed1995

[Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery].

Fifty patients with purulent infection of the abdominal cavity were treated with cefpiramide (Lek, Slovania). The analysis of the results showed that the clinical effect was favourable in 92 percent of the patients. The bacteriological efficacy amounted to 65.2 percent. The index of the isolates susceptibility was high (72 percent at the average). The concentration of cefpiramide in the bile from the bile common duct was low (23 micrograms/ml) as a result of its partial or complete obstruction. The adverse reaction (diarrhea) was stated in 1 patient.

Abdomen↗
PubMed1995

[Effectiveness of pefloxacin in the surgical clinic].

Pefloxacin (Rhone-Poulenc, France) was used prophylactically and therapeutically in 8 and 21 surgical inpatients respectively. The majority of the Enterobacteriaceae isolates were susceptible to pefloxacin (91 to 100 per cent). The isolates of Acinetobacter spp. and Pseudomonas aeruginosa were less susceptible (77 and 33.3 per cent respectively). The isolates of Staphylococcus aureus and S. epidermidis were mainly susceptible to the drug. The high antimicrobial activity of pefloxacin used therapeutically well correlated with the favourable time course of the main disease. When pefloxacin was used prophylactically the results were positive in all the cases. The drug tolerance in the majority of the cases was good. Only 2 patients developed allergic reactions as multiple minipunctate rash. After discontinuation of the drug use and short-term course of the desensitization the clinical sings of the allergic reactions disappeared in 3 days.

Anti-Infective Agents↗
PubMed1994

[Ofloxacin in the comprehensive therapy of complicated forms of wound infection].

A 5-year experience with the use of ofloxacin in the complex treatment of complicated wound infections showed that the drug had a broad spectrum of antimicrobial activity, was not toxic and well tolerated by the patients. The side effects were extremely rare. The antimicrobial activity of ofloxacin after its clinical use for 5 years did not practically change. The drug clinical and bacteriological efficacy in different groups of the patients ranged within 85-91 and 74-80 per cent respectively depending on the process severity. The failure of the therapy was as a rule associated with an insufficient surgical treatment of the purulent foci. It was more frequent in the patients with arteriosclerotic and diabetic gangrene of the lower extremities when due to various reasons the initial surgical operations were not radical. The short treatment courses (for not more than 5-7 days) or an early use of the drug tablets instead of the intravenous injections resulted from an insufficient experience with ofloxacin during the first years of its use. Such an unjustified tactics did not provide stable elimination of the pathogen. Our experience with ofloxacin in the treatment of various groups of patients with wound infections demonstrated that it should be considered as a reserve drug for the treatment of cases with complicated wound infections accompanied by infections of the respiratory and uropoietic organs requiring a long-term antibacterial therapy in hospitals and outpatient departments.

Combined Modality Therapy↗
PubMed1991

[Ciprofloxacin in the prevention and treatment of surgical infections].

A clinico-laboratory study on ciprofloxacin made by Bayer (Germany) was applied to patients with extended posttraumatic wounds and performed with the aim of preventing postoperative purulent complications in patients operated on the organs of the gastrointestinal tract. In the both groups ciprofloxacin was administered orally in doses of 500 and 1000 mg and intravenously in a dose of 200 mg. The results of the assay on ciprofloxacin sensitivity of the isolates from the wound excretion and urine showed that they were more sensitive to ciprofloxacin than to aminoglycosides and cephalosporins. 15 minutes after the intravenous administration the serum concentration of ciprofloxacin amounted to 7.5 +/- 0.9 micrograms/ml and in 6 hours it was equal to 0.45 +/- 0.45 micrograms/ml, the mean concentrations of ciprofloxacin being attained in the bile (8.7 +/- +/- 3.9 micrograms/ml), gallbladder wall (5.5 +/- 3.8 micrograms/g), liver (0.73 micrograms/g), muscles (1.93 micrograms/g) and tendon (0.15 microgram/g). After the oral administration in a dose of 500 mg ciprofloxacin was detected in the blood serum in an amount of 2.0 +/- 0.7 micrograms/ml in 1 hour and in an amount of 0.9 +/- 0.13 micrograms/ml in 6 hours. After the drug oral administration in a dose of 1000 mg the maximum concentrations were: 6.34 +/- 4.2 micrograms/ml on the average and 2.1 +/- 0.8 micrograms/ml in 6 hours (0.4 micrograms/g in the muscles, 1.4 micrograms/g in the skin and 0.34 micrograms/g in the bones). The study showed that ciprofloxacin was a highly efficient antimicrobial agent in the treatment of the complicated wound infections and the prophylaxis of the purulent complications during the postoperative period in the patients operated on gastrointestinal organs.

Administration, Oral↗